Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$297.03 +0.6%	$283.56	$253.30 ▼ $346.85	$159.72B	0.49	2.84 million shs	1.20 million shs
BIIB Biogen	$133.11 -0.8%	$128.17	$110.04 ▼ $236.48	$19.50B	0.14	1.45 million shs	694,328 shs
GILD Gilead Sciences	$112.09 +2.2%	$107.74	$70.21 ▼ $119.96	$139.43B	0.29	7.70 million shs	6.38 million shs
ILMN Illumina	$98.53 -0.7%	$87.18	$68.70 ▼ $156.66	$15.60B	1.36	2.15 million shs	2.09 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	-1.00%	+0.02%	+0.46%	-10.75%
BIIB Biogen	0.00%	+1.20%	+2.72%	+12.54%	-41.66%
GILD Gilead Sciences	0.00%	-1.47%	-0.31%	+2.95%	+56.72%
ILMN Illumina	0.00%	-1.18%	+14.17%	+32.23%	-14.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4333 of 5 stars	2.2	2.0	3.3	3.9	3.6	2.5	1.3
BIIB Biogen	4.8209 of 5 stars	4.2	3.0	0.0	3.7	3.3	1.7	1.9
GILD Gilead Sciences	4.9255 of 5 stars	1.4	5.0	4.2	4.1	4.0	2.5	3.1
ILMN Illumina	4.8676 of 5 stars	4.2	3.0	0.0	4.2	3.1	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.35	Hold	$307.82	3.63% Upside
BIIB Biogen	2.38	Hold	$188.48	41.60% Upside
GILD Gilead Sciences	2.77	Moderate Buy	$111.38	-0.63% Downside
ILMN Illumina	2.40	Hold	$125.11	26.97% Upside

Current Analyst Ratings Breakdown

Latest AMGN, BIIB, GILD, and ILMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	ILMN Illumina	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$125.00
7/9/2025	ILMN Illumina	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell	$85.00 ➝ $80.00
7/8/2025	ILMN Illumina	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$116.00 ➝ $128.00
6/27/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$328.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/24/2025	AMGN Amgen	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/24/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$305.00
6/24/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$77.00 ➝ $85.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.78	$30.56 per share	9.72	$10.93 per share	27.18
BIIB Biogen	$9.68B	2.02	$22.91 per share	5.81	$114.71 per share	1.16
GILD Gilead Sciences	$28.75B	4.85	$7.02 per share	15.96	$15.44 per share	7.26
ILMN Illumina	$4.37B	3.57	$4.66 per share	21.16	$14.96 per share	6.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	27.10	13.89	2.67	17.39%	176.11%	12.39%	8/5/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	13.14	8.06	1.07	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	23.60	13.82	0.71	20.76%	51.93%	17.40%	8/6/2025 (Estimated)
ILMN Illumina	-$1.22B	-$6.07	N/A	19.09	1.95	-22.25%	25.54%	8.62%	8/5/2025 (Estimated)

Latest AMGN, BIIB, GILD, and ILMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BIIB Biogen	$4.11	N/A	N/A	N/A	$2.32 billion	N/A
8/5/2025	Q2 2025	AMGN Amgen	$5.21	N/A	N/A	N/A	$8.86 billion	N/A
8/5/2025	Q2 2025	ILMN Illumina	$1.02	N/A	N/A	N/A	$1.12 billion	N/A
5/8/2025	Q1 2025	ILMN Illumina	$0.96	$0.97	+$0.01	$0.82	$1.03 billion	$1.04 billion
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.21%	N/A	86.86%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.82%	N/A	66.53%	10 Years
ILMN Illumina	N/A	N/A	N/A	N/A	N/A

Latest AMGN, BIIB, GILD, and ILMN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	8.70	1.17	0.88
BIIB Biogen	0.27	1.44	1.01
GILD Gilead Sciences	1.16	1.37	1.23
ILMN Illumina	0.63	1.86	1.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
GILD Gilead Sciences	83.67%
ILMN Illumina	89.42%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BIIB Biogen	0.18%
GILD Gilead Sciences	0.27%
ILMN Illumina	0.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.71 million	534.00 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
GILD Gilead Sciences	17,600	1.24 billion	1.24 billion	Optionable
ILMN Illumina	9,030	158.30 million	158.03 million	Optionable

AMGN, BIIB, GILD, and ILMN Headlines

Recent News About These Companies

OVERSEA CHINESE BANKING Corp Ltd Has $47.07 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

July 14 at 8:23 AM | marketbeat.com

Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Raised by Slow Capital Inc.

July 14 at 7:10 AM | marketbeat.com

Illumina, Inc. (NASDAQ:ILMN) Stock Position Raised by Stephens Investment Management Group LLC

July 14 at 5:45 AM | marketbeat.com

Illumina (NASDAQ:ILMN) Stock Rating Lowered by Scotiabank

July 14 at 2:47 AM | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of "Hold" from Brokerages

July 14 at 2:10 AM | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of "Hold" by Analysts

July 14 at 2:10 AM | marketbeat.com

Notable healthcare headlines for the week: Trump’s tariff threat, Merck, UnitedHealth and Moderna in focus

July 13 at 6:49 PM | msn.com

Notable analyst calls this week: Tesla, Microsoft and Illumina among top picks

July 12 at 7:17 PM | msn.com

Scotiabank Downgrades Illumina (ILMN)

July 12 at 9:15 AM | msn.com

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds

July 12 at 4:15 AM | seekingalpha.com

Illumina (NASDAQ:ILMN) Cut to Strong Sell at Citigroup

July 12 at 4:03 AM | americanbankingnews.com

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds

July 12 at 4:01 AM | seekingalpha.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN) and Gilead Sciences (GILD)

July 11 at 6:06 PM | theglobeandmail.com

Evercore ISI Reaffirms Their Buy Rating on Illumina (ILMN)

July 11 at 6:06 PM | theglobeandmail.com

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

July 11 at 3:13 PM | seekingalpha.com

Illumina (ILMN) Faces Downgrades Amid Concerns Over 2026 Outlook

July 11 at 11:10 AM | gurufocus.com

Illumina downgraded at Scotiabank on outlook; Danaher, Thermo Fisher upgraded

July 11 at 10:46 AM | seekingalpha.com

Ownership Capital B.V. Has $45.77 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

July 11 at 8:41 AM | marketbeat.com

Illumina (NASDAQ:ILMN) Cut to Sector Perform at Scotiabank

July 11 at 8:15 AM | marketbeat.com

Scotiabank Adjusts Illumina (ILMN) Rating Amid Market Uncertainty | ILMN Stock News

July 11 at 7:17 AM | gurufocus.com

Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Weil Company Inc.

July 11 at 7:12 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMGN, BIIB, GILD, and ILMN Company Descriptions

Amgen NASDAQ:AMGN

$297.03 +1.76 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$295.13 -1.90 (-0.64%)

As of 05:21 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$133.11 -1.10 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$133.16 +0.05 (+0.04%)

As of 05:21 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$112.09 +2.45 (+2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$112.30 +0.20 (+0.18%)

As of 05:21 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Illumina NASDAQ:ILMN

$98.53 -0.72 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$98.10 -0.42 (-0.43%)

As of 05:15 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time